Trial Profile
MK 5172 administered as ascending doses ranging from 100-800 mg/day in male patients with chronic genotype 1 or 3 hepatitis C virus
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Nov 2011
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics
- 23 Nov 2011 New trial record
- 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.